Tang Xiaowen, Yang Lin, Li Zheng, Nalin Ansel P, Dai Haiping, Xu Ting, Yin Jia, You Fengtao, Zhu Mingqing, Shen Wenhong, Chen Guanghua, Zhu Xiaming, Wu Depei, Yu Jianhua
Institute of Blood and Bone Marrow Transplantation Suzhou, China.
Collaborative Innovation Center of Hematology, Soochow University Suzhou, China.
Am J Cancer Res. 2018 Jun 1;8(6):1083-1089. eCollection 2018.
CAR T cells have shown clinical efficacy for acute lymphoblastic leukemia, but this therapy has not been effective for acute myeloid leukemia (AML), and other treatment options are needed. Theoretically, CAR-NK cells have a more favorable toxicity profile compared to CAR T cells, especially in avoiding adverse effects such as cytokine release syndrome. However, the clinical evidence for this has not yet been reported. In the current study, we tested the safety of CD33-CAR NK cells in patients with relapsed and refractory AML. At doses up to 5 × 10 (5 billion) cells per patient, no significant adverse effects were observed. CAR NK-92 cells can be produced at much lower cost compared to CAR T cells, and we believe after being optimized, they will be widely accessible for the treatment of cancer.
嵌合抗原受体（CAR）T细胞已在急性淋巴细胞白血病中显示出临床疗效，但该疗法对急性髓系白血病（AML）无效，因此需要其他治疗选择。从理论上讲，与CAR T细胞相比，CAR-NK细胞具有更有利的毒性特征，尤其是在避免诸如细胞因子释放综合征等不良反应方面。然而，目前尚未有相关临床证据报道。在本研究中，我们测试了CD33-CAR NK细胞在复发难治性AML患者中的安全性。在每位患者高达5×10⁵（50亿）个细胞的剂量下，未观察到明显的不良反应。与CAR T细胞相比，CAR NK-92细胞的生产成本要低得多，我们相信经过优化后，它们将广泛应用于癌症治疗。
